CHURCHILL MANAGEMENT Corp Has $8.40 Million Stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

CHURCHILL MANAGEMENT Corp grew its position in GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report) by 4.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 107,427 shares of the company's stock after purchasing an additional 4,573 shares during the period. CHURCHILL MANAGEMENT Corp's holdings in GE HealthCare Technologies were worth $8,399,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in GEHC. Mesirow Financial Investment Management Inc. raised its position in GE HealthCare Technologies by 39.6% during the third quarter. Mesirow Financial Investment Management Inc. now owns 4,084 shares of the company's stock valued at $383,000 after acquiring an additional 1,159 shares in the last quarter. LMR Partners LLP bought a new position in shares of GE HealthCare Technologies during the 3rd quarter valued at $7,387,000. Principal Financial Group Inc. raised its holdings in shares of GE HealthCare Technologies by 1.9% during the 3rd quarter. Principal Financial Group Inc. now owns 1,009,910 shares of the company's stock valued at $94,780,000 after purchasing an additional 19,010 shares in the last quarter. Everence Capital Management Inc. boosted its holdings in GE HealthCare Technologies by 118.2% in the fourth quarter. Everence Capital Management Inc. now owns 18,870 shares of the company's stock worth $1,475,000 after purchasing an additional 10,220 shares in the last quarter. Finally, B. Metzler seel. Sohn & Co. Holding AG acquired a new position in GE HealthCare Technologies during the third quarter worth $1,396,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently issued reports on GEHC shares. Jefferies Financial Group upgraded GE HealthCare Technologies from a "hold" rating to a "buy" rating and upped their price target for the stock from $95.00 to $103.00 in a research note on Wednesday, January 8th. BTIG Research raised GE HealthCare Technologies from a "neutral" rating to a "buy" rating and set a $100.00 target price for the company in a research report on Wednesday, September 18th. Evercore ISI lifted their price target on shares of GE HealthCare Technologies from $98.00 to $102.00 and gave the company an "outperform" rating in a research report on Tuesday, October 1st. Stifel Nicolaus boosted their price objective on shares of GE HealthCare Technologies from $100.00 to $102.00 and gave the stock a "buy" rating in a research note on Monday, September 30th. Finally, UBS Group lowered shares of GE HealthCare Technologies from a "neutral" rating to a "sell" rating and lowered their target price for the company from $84.00 to $74.00 in a research note on Thursday, September 26th. One analyst has rated the stock with a sell rating, four have given a hold rating, nine have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $96.00.

Insider Activity at GE HealthCare Technologies

In related news, CEO Roland Rott sold 3,577 shares of GE HealthCare Technologies stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $86.48, for a total transaction of $309,338.96. Following the transaction, the chief executive officer now owns 24,298 shares of the company's stock, valued at $2,101,291.04. This trade represents a 12.83 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.27% of the stock is currently owned by corporate insiders.

GE HealthCare Technologies Trading Up 1.6 %

Shares of NASDAQ GEHC traded up $1.34 during mid-day trading on Thursday, hitting $85.00. The company's stock had a trading volume of 2,115,686 shares, compared to its average volume of 3,271,499. GE HealthCare Technologies Inc. has a one year low of $71.31 and a one year high of $94.55. The company's fifty day simple moving average is $82.07 and its 200-day simple moving average is $84.26. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.23 and a quick ratio of 0.98. The stock has a market cap of $38.83 billion, a price-to-earnings ratio of 23.35, a price-to-earnings-growth ratio of 2.80 and a beta of 1.11.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.14 earnings per share for the quarter, topping analysts' consensus estimates of $1.06 by $0.08. GE HealthCare Technologies had a net margin of 8.56% and a return on equity of 25.19%. The business had revenue of $4.86 billion during the quarter, compared to the consensus estimate of $4.87 billion. During the same period in the previous year, the firm posted $0.99 earnings per share. GE HealthCare Technologies's revenue for the quarter was up .9% compared to the same quarter last year. On average, sell-side analysts anticipate that GE HealthCare Technologies Inc. will post 4.3 earnings per share for the current fiscal year.

GE HealthCare Technologies Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Tuesday, January 14th will be paid a dividend of $0.035 per share. The ex-dividend date of this dividend is Tuesday, January 14th. This is a boost from GE HealthCare Technologies's previous quarterly dividend of $0.03. This represents a $0.14 dividend on an annualized basis and a dividend yield of 0.16%. GE HealthCare Technologies's payout ratio is 3.30%.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.